Citations to this article
Benjamin Y. Jin, … , Cornelia L. Trimble, Christian S. Hinrichs
Published April 19, 2018
Citation Information: JCI Insight. 2018;3(8):e99488. https://doi.org/10.1172/jci.insight.99488.
Citation Information: JCI Insight. 2018;3(8):e99488. https://doi.org/10.1172/jci.insight.99488.
Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model
Abstract
T cell receptor (TCR) T cell therapy is a promising cancer treatment modality. However, its successful development for epithelial cancers may depend on the identification of high-avidity TCRs directed against tumor-restricted target antigens. The human papillomavirus (HPV) E7 antigen is an attractive therapeutic target that is constitutively expressed by HPV+ cancers but not by healthy tissues. It is unknown if genetically engineered TCR T cells that target E7 can mediate regression of HPV+ cancers. We identified an HPV-16 E7-specific, HLA-A*02:01-restricted TCR from a uterine cervix biopsy from a woman with cervical intraepithelial neoplasia. This TCR demonstrated high functional avidity, with CD8 coreceptor–independent tumor targeting. Human T cells transduced to express the TCR specifically recognized and killed HPV-16+ cervical and oropharyngeal cancer cell lines and mediated regression of established HPV-16+ human cervical cancer tumors in a mouse model. These findings support the therapeutic potential of this approach and established the basis for an E7 TCR gene therapy clinical trial in patients with metastatic HPV+ cancers (NCT02858310).
Authors
Benjamin Y. Jin, Tracy E. Campbell, Lindsey M. Draper, Sanja Stevanović, Bianca Weissbrich, Zhiya Yu, Nicholas P. Restifo, Steven A. Rosenberg, Cornelia L. Trimble, Christian S. Hinrichs
Total citations by year
Citation information
Citations to this article (82)
| Title and authors | Publication | Year |
|---|---|---|
|
Single-cell sequencing of tumour infiltrating lymphocytes efficiently identifies tumour-reactive T cell receptors based on T-cell activation score
Chaoting Zhang, Shance Li, Luyan Shen, Xia Teng, Yefei Xiao, Zheming Lu |
Cancer Immunology, Immunotherapy | 2024 |
|
Lymph Node–Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors
Drakes DJ, Abbas AM, Shields J, Steinbuck MP, Jakubowski A, Seenappa LM, Haqq CM, DeMuth PC |
Cancer immunology research | 2024 |
|
Cooperative Armoring of CAR and TCR T Cells by T Cell-Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy.
Nguyen R, Doubrovina E, Mousset CM, Jin BY, Okada R, Zhang X, Clavel A, Reyes-Gonzalez JM, Dyomin V, Diaz L, Zhang L, Abbas S, Sun M, Hsieh CM, Ho M, Shern JF, Gulley JL, Hinrichs CS |
Clinical cancer research | 2024 |
|
Tsyn-seq: a T cell synapse–based antigen identification platform
Jin Y, Miyama T, Brown A, Hayase T, Song X, Singh AK, Huang L, Flores II, McDaniel LK, Glover I, Halsey TM, Prasad R, Chapa V, Ahmed S, Zhang J, Rai K, Peterson CB, Lizee G, Karmouch J, Hayase E, Molldrem JJ, Chang CC, Tsai WB, Jenq RR |
Cancer immunology research | 2024 |
|
The recent advancement of TCR-T cell therapies for cancer treatment: TCR-T cell therapies for cancer treatment
Zhao X, Shao S, Hu L |
Acta Biochimica et Biophysica Sinica | 2024 |
|
Engineered T Cell Receptor for Cancer Immunotherapy
Lee SW, Lee HM |
Biomolecules & therapeutics | 2024 |
|
Mathematical model for IL-2-based cancer immunotherapy
Dixon M, Phan TA, Dallon JC, Tian JP |
Mathematical Biosciences | 2024 |
|
Leveraging oncovirus-derived antigen against the viral malignancies in adoptive cell therapies
Zhang W, Zeng M, Li Y, Yu L |
Biomarker Research | 2024 |
|
TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges.
Golikova EA, Alshevskaya AA, Alrhmoun S, Sivitskaya NA, Sennikov SV |
Journal of translational medicine | 2024 |
|
Conserved allomorphs of MR1 drive the specificity of MR1-restricted TCRs.
Cornforth TV, Moyo N, Cole S, Lam EPS, Lobry T, Wolchinsky R, Lloyd A, Ward K, Denham EM, Masi G, Qing Yun PT, Moore C, Dhaouadi S, Besra GS, Veerapen N, Illing PT, Vivian JP, Raynes JM, Le Nours J, Purcell AW, Kundu S, Silk JD, Williams L, Papa S, Rossjohn J, Howie D, Dukes J |
Frontiers in oncology | 2024 |
|
CAR-T cells based on a TCR mimic nanobody targeting HPV16 E6 exhibit antitumor activity against cervical cancer
Duan Z, Li D, Li N, Lin S, Ren H, Hong J, Hinrichs CS, Ho M |
Molecular Therapy Oncology | 2024 |
|
Tumor cells fail to present MHC-II restricted epitopes derived from oncogenes to CD4+ T cells
Spencer Brightman, Martin Naradikian, Rukman Thota, Angelica Becker, Leslie Montero, Milad Bahmanof, Ashmitaa Premlal, Jason Greenbaum, Bjoern Peters, Ezra Cohen, Aaron Miller, Stephen Schoenberger |
JCI Insight | 2023 |
|
Pathogen-specific T Cells: Targeting Old Enemies and New Invaders in Transplantation and Beyond
Papadopoulou A, Alvanou M, Karavalakis G, Tzannou I, Yannaki E |
HemaSphere | 2023 |
|
TCR-engineered T cell therapy in solid tumors: State of the art and perspectives
Baulu E, Gardet C, Chuvin N, Depil S |
Science Advances | 2023 |
|
The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination
Mühlenbruch L, Abou-Kors T, Dubbelaar ML, Bichmann L, Kohlbacher O, Bens M, Thomas J, Ezić J, Kraus JM, Kestler HA, von Witzleben A, Mytilineos J, Fürst D, Engelhardt D, Doescher J, Greve J, Schuler PJ, Theodoraki MN, Brunner C, Hoffmann TK, Rammensee HG, Walz JS, Laban S |
British Journal of Cancer | 2023 |
|
EDA-E7 Activated DCs Induces Cytotoxic T Lymphocyte Immune Responses against HPV Expressing Cervical Cancer in Human Setting
Feng J, Liu Y, Zhuang N, Chai Z, Liu L, Qian C, Li J, Shan J |
Human vaccines | 2023 |
|
The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer—Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy
Starska-Kowarska K |
Cancers | 2023 |
|
Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer
Saba NF, Pamulapati S, Patel B, Mody M, Strojan P, Takes R, Mäkitie AA, Cohen O, Pace-Asciak P, Vermorken JB, Bradford C, Forastiere A, Teng Y, Wieland A, Ferlito A |
Cancers | 2023 |
|
T cell immunotherapy for cervical cancer: challenges and opportunities
Yu L, Lanqing G, Huang Z, Xin X, Minglin L, Fa-hui L, Zou H, Min J |
Frontiers in immunology | 2023 |
|
Phenotypic plasticity and reduced tissue retention of exhausted tumor-infiltrating T cells following neoadjuvant immunotherapy in head and neck cancer
Sievers C, Craveiro M, Friedman J, Robbins Y, Yang X, Bai K, Nguyen A, Redman JM, Chari R, Soon-Shiong P, Schlom J, Gulley J, Allen CT |
Cancer Cell | 2023 |
|
Immunotherapy in Anal Cancer.
Dhawan N, Afzal MZ, Amin M |
Current oncology (Toronto, Ont.) | 2023 |
|
N-Acetyl-L-Cysteine Reduces Cervical Carcinogenesis by Promoting Apoptosis.
Guo W, Jing W |
Drugs in R & D | 2023 |
|
The Tumor-Specific Immune Landscape in HPV+ Head and Neck Cancer
Conarty JP, Wieland A |
Viruses | 2023 |
|
Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross-presentation
Cieniewicz B, Bhatta A, Torabi D, Baichoo P, Saxton M, Arballo A, Nguyen L, Thomas S, Kethar H, Kukutla P, Shoaga O, Yu B, Yang Z, Fate M, Oliveira E, Ning H, Corey L, Corey D |
Molecular Therapy | 2023 |
|
Multi-tiered approach to detect autoimmune cross-reactivity of therapeutic T cell receptors
Ishii K, Davies JS, Sinkoe AL, Nguyen KA, Norberg SM, McIntosh CP, Kadakia T, Serna C, Rae Z, Kelly MC, Hinrichs CS |
Science Advances | 2023 |
|
A luminescence-based method to assess antigen presentation and antigen-specific T cell responses for in vitro screening of immunomodulatory checkpoints and therapeutics.
Álvarez Freile J, Qi Y, Jacob L, Lobo MF, Lourens HJ, Huls G, Bremer E |
Frontiers in immunology | 2023 |
|
Advancing Immunotherapies for HPV-Related Cancers: Exploring Novel Vaccine Strategies and the Influence of Tumor Microenvironment.
Silva AJD, Moura IA, Gama MATMD, Leal LRS, Pinho SS, Espinoza BCF, Santos DLD, Santos VEP, Sena MGAM, Invenção MDCV, Macêdo LS, França Neto PL, Freitas AC |
Human vaccines | 2023 |
|
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells
Li J, Xiao Z, Wang D, Jia L, Nie S, Zeng X, Hu W |
Molecular Cancer | 2023 |
|
A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo
Giannakopoulou E, Lehander M, Virding Culleton S, Yang W, Li Y, Karpanen T, Yoshizato T, Rustad EH, Nielsen MM, Bollineni RC, Tran TT, Delic-Sarac M, Gjerdingen TJ, Douvlataniotis K, Laos M, Ali M, Hillen A, Mazzi S, Chin DW, Mehta A, Holm JS, Bentzen AK, Bill M, Griffioen M, Gedde-Dahl T, Lehmann S, Jacobsen SE, Woll PS, Olweus J |
Nature cancer | 2023 |
|
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome.
Klebanoff CA, Chandran SS, Baker BM, Quezada SA, Ribas A |
Nature reviews. Drug discovery | 2023 |
|
Epigenetic and Genetic Keys to Fight HPV-Related Cancers
Folliero V, Dell\u2019Annunziata F, Chianese A, Morone MV, Mensitieri F, Di Spirito F, Mollo A, Amato M, Galdiero M, Dal Piaz F, Pagliano P, Rinaldi L, Franci G |
Cancers | 2023 |
|
Engineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptors.
Johnston AC, Alicea GM, Lee CC, Patel PV, Hanna EA, Vaz E, Forjaz A, Wan Z, Nair PR, Lim Y, Chen T, Du W, Kim D, Nichakawade TD, Rebecca VW, Bonifant CL, Fan R, Kiemen AL, Wu PH, Wirtz D |
bioRxiv : the preprint server for biology | 2023 |
|
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
P Shafer, L Kelly, V Hoyos |
Frontiers in immunology | 2022 |
|
A TCR mimic monoclonal antibody for the HPV-16 E7-epitope p11-19/HLA-A*02:01 complex
T Dao, S Mun, T Korontsvit, A Khan, M Pohl, T White, M Klatt, D Andrew, I Lorenz, D Scheinberg, Z Zheng |
PloS one | 2022 |
|
Determining if T cell antigens are naturally processed and presented on HLA class I molecules
J Friedman, S Gunti, M Lee, K Bai, C Hinrichs, C Allen |
BMC Immunology | 2022 |
|
TCR engineered T cells for solid tumor immunotherapy
Y Zhang, Z Liu, W Wei, Y Li |
Experimental Hematology and Oncology | 2022 |
|
Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story
Drakopoulou E, Anagnou NP, Pappa KI |
Cancers | 2022 |
|
Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes.
Duhen T, Gough MJ, Leidner RS, Stanton SE |
2022 | |
|
Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade.
Bai K, Norberg SM, Sievers C, Meyer T, Friedman J, Hinrichs C, Allen CT |
Head & Neck | 2022 |
|
Identification of novel HLA-A*11:01-restricted HPV16 E6/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy
Xiong C, Huang L, Kou H, Wang C, Zeng X, Sun H, Liu S, Wu B, Li J, Wang X, Wang Z, Chen L |
Journal for ImmunoTherapy of Cancer | 2022 |
|
The association of cervicovaginal Langerhans cells with clearance of human papillomavirus.
Dai W, Gui L, Du H, Li S, Wu R |
Frontiers in immunology | 2022 |
|
Rapid generation of genetically engineered T cells for the treatment of virus‐related cancers
Jiang J, Xia M, Zhang L, Chen X, Zhao Y, Zeng C, Yang H, Liang P, Li G, Li N, Qi H, Wei T, Ren L |
Cancer Science | 2022 |
|
Immune landscape and immunotherapy for penile cancer
Tang Y, Hu X, Wu K, Li X |
Frontiers in immunology | 2022 |
|
Non-viral precision T cell receptor replacement for personalized cell therapy
Foy SP, Jacoby K, Bota DA, Hunter T, Pan Z, Stawiski E, Ma Y, Lu W, Peng S, Wang CL, Yuen B, Dalmas O, Heeringa K, Sennino B, Conroy A, Bethune MT, Mende I, White W, Kukreja M, Gunturu S, Humphrey E, Hussaini A, An D, Litterman AJ, Quach BB, Ng AH, Lu Y, Smith C, Campbell KM, Anaya D, Skrdlant L, Huang EY, Mendoza V, Mathur J, Dengler L, Purandare B, Moot R, Yi MC, Funke R, Sibley A, Stallings-Schmitt T, Oh DY, Chmielowski B, Abedi M, Yuan Y, Sosman JA, Lee SM, Schoenfeld AJ, Baltimore D, Heath JR, Franzusoff A, Ribas A, Rao AV, Mandl SJ |
Nature | 2022 |
|
Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies
Kowalczyk JT, Fabian KP, Padget MR, Lopez DC, Hoke AT, Allen CT, Hermsen M, London, NR Jr, Hodge JW |
Journal for ImmunoTherapy of Cancer | 2022 |
|
Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapies
Song HW, Somerville RP, Stroncek DF, Highfill SL |
International Reviews of Immunology | 2022 |
|
Towards Novel Gene and Cell Therapy Approaches for Cervical Cancer
Polten R, Kutle I, Hachenberg J, Klapdor R, Morgan M, Schambach A |
Cancers | 2022 |
|
Engineered T Cell Therapy for Viral and Non-viral Epithelial Cancers
Norberg SM, Hinrichs CS |
Cancer Cell | 2022 |
|
Induction of EBV latent membrane protein-2A (LMP2A)-specific T cells and construction of individualized TCR-engineered T cells for EBV-associated malignancies
C Zhang, Q Tan, S Li, L Shen, J Zhang, Y Liu, W Yang, Z Lu |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
MY Lee, Y Robbins, C Sievers, J Friedman, HA Sater, PE Clavijo, N Judd, E Tsong, C Silvin, P Soon-Shiong, MR Padget, J Schlom, J Hodge, C Hinrichs, C Allen |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Immunotherapy for HPV Malignancies
MY Lee, CT Allen |
Seminars in radiation oncology | 2021 |
|
Prognostic and therapeutic TILs of cervical cancer—Current advances and future perspectives
Y Tang, AX Zhang, G Chen, Y Wu, W Gu |
Molecular Therapy — Oncolytics | 2021 |
|
Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons
Q Zhao, Y Jiang, S Xiang, PJ Kaboli, J Shen, Y Zhao, X Wu, F Du, M Li, CH Cho, J Li, Q Wen, T Liu, T Yi, Z Xiao |
Frontiers in immunology | 2021 |
|
Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis
MY Lee, S Metenou, DE Brough, H Sabzevari, K Bai, C Jochems, J Schlom, CT Allen |
npj Vaccines | 2021 |
|
T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes
M Ali, E Giannakopoulou, Y Li, M Lehander, SV Culleton, W Yang, C Knetter, MC Odabasi, RC Bollineni, X Yang, Z Foldvari, ML Böschen, E Taraldsrud, E Strønen, M Toebes, A Hillen, S Mazzi, AH de Ru, GM Janssen, A Kolstad, GE Tjønnfjord, BA Lie, M Griffioen, S Lehmann, LT Osnes, J Buechner, KC Garcia, TN Schumacher, PA van Veelen, M Leisegang, SE Jacobsen, P Woll, J Olweus |
Nature Biotechnology | 2021 |
|
Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities
Y Xu, J Jiang, Y Wang, W Wang, H Li, W Lai, Z Zhou, W Zhu, Z Xiang, Z Wang, Z Zhu, L Yu, X Huang, H Zheng, S Wu |
Frontiers in immunology | 2021 |
|
Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers
X Wang, ML Sandberg, AD Martin, KR Negri, GB Gabrelow, DP Nampe, ML Wu, ME McElvain, DT Warshaviak, WH Lee, J Oh, ME Daris, F Chai, C Yao, J Furney, C Pigott, A Kamb, H Xu |
Journal of immunotherapy (Hagerstown, Md. : 1997) | 2021 |
|
T-Cell Receptor Mimic Antibodies for Cancer Immunotherapy
Z Duan, M Ho |
Molecular cancer therapeutics | 2021 |
|
An efficient method to identify virus-specific TCRs for TCR-T cell immunotherapy against virus-associated malignancies
L Chen, L Dong, Y Ma, J Wang, D Qiao, G Tian, M Wang |
BMC Immunology | 2021 |
|
Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic
X Zhang, M Luo, SR Dastagir, M Nixon, A Khamhoung, A Schmidt, A Lee, N Subbiah, DC McLaughlin, CL Moore, M Gribble, N Bayhi, V Amin, R Pepi, S Pawar, TJ Lyford, V Soman, J Mellen, CL Carpenter, LA Turka, TJ Wickham, TF Chen |
Nature Communications | 2021 |
|
Identification of cross-reactive CD8+ T cell receptors with high functional avidity to a SARS-CoV-2 immunodominant epitope and its natural mutant variants
C Hu, M Shen, X Han, Q Chen, L Li, S Chen, J Zhang, F Gao, W Wang, Y Wang, T Li, S Li, J Huang, J Wang, J Zhu, D Chen, Q Wu, K Tao, D Pang, A Jin |
Genes & Diseases | 2021 |
|
SARS‐CoV‐2‐reactive T‐cell receptors isolated from convalescent COVID‐19 patients confer potent T‐cell effector function
F Brunk, A Moritz, A Nelde, T Bilich, N Casadei, SA Fraschka, JS Heitmann, S Hörber, A Peter, HG Rammensee, H Singh, J Walz, D Maurer, C Wagner |
European Journal of Immunology | 2021 |
|
CD8+ T Cell Exhaustion in Cancer
JS Dolina, NV Braeckel-Budimir, GD Thomas, S Salek-Ardakani |
Frontiers in immunology | 2021 |
|
Immunotherapy Approaches in HPV-Associated Head and Neck Cancer
R Julian, M Savani, JE Bauman |
Cancers | 2021 |
|
Ultrasonic Elastography Combined with Human Papilloma Virus Detection Based on Intelligent Denoising Algorithm in Diagnosis of Cervical Intraepithelial Neoplasia
L Sun, X Shan, Q Dong, C Wu, M Shan, H Guo, R Lu, O Khalaf |
Computational and mathematical methods in medicine | 2021 |
|
TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers
Nagarsheth NB, Norberg SM, Sinkoe AL, Adhikary S, Meyer TJ, Lack JB, Warner AC, Schweitzer C, Doran SL, Korrapati S, Stevanović S, Trimble CL, Kanakry JA, Bagheri MH, Ferraro E, Astrow SH, Bot A, Faquin WC, Stroncek D, Gkitsas N, Highfill S, Hinrichs CS |
Nature Medicine | 2021 |
|
Recent developments in immunotherapy of cancers caused by human papillomaviruses
E Fakhr, Ž Modic, A CidArregui |
Immunology | 2020 |
|
Targeted Gene Delivery Therapies for Cervical Cancer
Á Áyen, YJ Martínez, H Boulaiz |
Cancers | 2020 |
|
Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy
A Pal, R Kundu |
Frontiers in microbiology | 2020 |
|
Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors
V Leko, SA Rosenberg |
Cancer Cell | 2020 |
|
Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms
I Etxeberria, I Olivera, E Bolaños, A Cirella, Á Teijeira, P Berraondo, I Melero |
Cellular and Molecular Immunology | 2020 |
|
Adoptive T cell therapy: Boosting the immune system to fight cancer
E Leon, R Ranganathan, B Savoldo |
Seminars in Immunology | 2020 |
|
A multivariate, quantitative assay that disentangles key kinetic parameters of primary human T cell function in vitro
G Huang, D Nampe, J Yi, G Gabrelow, K Negri, A Kamb, H Xu, N Gangopadhyay |
PloS one | 2020 |
|
Computational stabilization of T cell receptors allows pairing with antibodies to form bispecifics
K Froning, J Maguire, A Sereno, F Huang, S Chang, K Weichert, A Frommelt, J Dong, X Wu, H Austin, E Conner, J Fitchett, A Heng, D Balasubramaniam, M Hilgers, B Kuhlman, S Demarest |
Nature Communications | 2020 |
|
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
SS Chandran, CA Klebanoff |
Immunological Reviews | 2019 |
|
Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models
L Zhang, JS Davies, C Serna, Z Yu, NP Restifo, SA Rosenberg, RA Morgan, CS Hinrichs |
Journal for ImmunoTherapy of Cancer | 2019 |
|
Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy
CF Soon, S Zhang, PV Suneetha, DA Antunes, MP Manns, S Raha, C Schultze-Florey, I Prinz, H Wedemeyer, MS Chen, M Cornberg |
Frontiers in immunology | 2019 |
|
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
EE Cohen, RB Bell, CB Bifulco, B Burtness, ML Gillison, KJ Harrington, QT Le, NY Lee, R Leidner, RL Lewis, L Licitra, H Mehanna, LK Mell, A Raben, AG Sikora, R Uppaluri, F Whitworth, DP Zandberg, RL Ferris |
Journal for ImmunoTherapy of Cancer | 2019 |
|
Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma
Q Tan, C Zhang, W Yang, Y Liu, P Heyilimu, D Feng, L Xing, Y Ke, Z Lu |
Journal for ImmunoTherapy of Cancer | 2019 |
|
T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy
Sharma P, Kranz DM |
Critical reviews in immunology | 2019 |
|
The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex
C Jochems, SR Tritsch, KM Knudson, SR Gameiro, CS Rumfield, ST Pellom, YM ll, R Newman, W Marcus, C Szeto, S Rabizadeh, HC Wong, P Soon-Shiong, J Schlom |
OncoImmunology | 2018 |
|
A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus–associated Epithelial Cancers
S Stevanović, SR Helman, JR Wunderlich, MM Langhan, SL Doran, ML Kwong, RP Somerville, CA Klebanoff, US Kammula, RM Sherry, JC Yang, SA Rosenberg, CS Hinrichs |
Clinical cancer research | 2018 |
